Novo Integrated Sciences Performance
| NVOSDelisted Stock | USD 0.04 0.01 17.57% |
The company secures a Beta (Market Risk) of 3.37, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Novo Integrated will likely underperform. At this point, Novo Integrated Sciences has a negative expected return of -4.75%. Please make sure to verify Novo Integrated's value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Novo Integrated Sciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Novo Integrated Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 2.2 M |
Novo |
Novo Integrated Relative Risk vs. Return Landscape
If you would invest 23.00 in Novo Integrated Sciences on October 22, 2024 and sell it today you would lose (18.59) from holding Novo Integrated Sciences or give up 80.83% of portfolio value over 90 days. Novo Integrated Sciences is currently does not generate positive expected returns and assumes 29.2381% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Novo, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Novo Integrated Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novo Integrated's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Novo Integrated Sciences, and traders can use it to determine the average amount a Novo Integrated's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1626
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NVOS |
Estimated Market Risk
| 29.24 actual daily | 96 96% of assets are less volatile |
Expected Return
| -4.75 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Novo Integrated is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novo Integrated by adding Novo Integrated to a well-diversified portfolio.
Novo Integrated Fundamentals Growth
Novo Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Novo Integrated, and Novo Integrated fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novo Pink Sheet performance.
| Return On Equity | -1.35 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (1.80) % | ||||
| Operating Margin | (0.80) % | ||||
| Current Valuation | 5.8 M | ||||
| Shares Outstanding | 19.05 M | ||||
| Price To Book | 0.29 X | ||||
| Price To Sales | 0.21 X | ||||
| Revenue | 12.57 M | ||||
| EBITDA | (5.63 M) | ||||
| Cash And Equivalents | 12.68 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 4.47 M | ||||
| Debt To Equity | 0.48 % | ||||
| Book Value Per Share | 0.52 X | ||||
| Cash Flow From Operations | (2.24 M) | ||||
| Earnings Per Share | (0.41) X | ||||
| Total Asset | 35.56 M | ||||
| Retained Earnings | (67.03 M) | ||||
About Novo Integrated Performance
Assessing Novo Integrated's fundamental ratios provides investors with valuable insights into Novo Integrated's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Novo Integrated is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary health care related products and services. Novo Integrated Sciences, Inc. operates as a subsidiary of ALMC-ASAP Holdings, Inc. Novo Integrated operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.Things to note about Novo Integrated Sciences performance evaluation
Checking the ongoing alerts about Novo Integrated for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Novo Integrated Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novo Integrated is not yet fully synchronised with the market data | |
| Novo Integrated generated a negative expected return over the last 90 days | |
| Novo Integrated has high historical volatility and very poor performance | |
| Novo Integrated has some characteristics of a very speculative penny stock | |
| Novo Integrated has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 12.57 M. Net Loss for the year was (13.27 M) with profit before overhead, payroll, taxes, and interest of 3.82 M. | |
| Novo Integrated Sciences currently holds about 12.68 M in cash with (2.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Novo Integrated's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novo Integrated's stock is overvalued or undervalued compared to its peers.
- Examining Novo Integrated's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novo Integrated's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novo Integrated's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novo Integrated's pink sheet. These opinions can provide insight into Novo Integrated's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Novo Pink Sheet
If you are still planning to invest in Novo Integrated Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Novo Integrated's history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |